Literature DB >> 33073973

Light-Responsive Core-Shell Nanoplatform for Bimodal Imaging-Guided Photothermal Therapy-Primed Cancer Immunotherapy.

Wei Zhang1, Cun-Cheng Zhang1, Xing-Yue Wang1, Lin Li1, Qiao-Qi Chen1, Wei-Wei Liu1, Yang Cao1, Hai-Tao Ran1.   

Abstract

Photothermal therapy (PTT) as a noninvasive and effective thermal therapeutic approach has attracted tremendously increasing interest because it can effectively eliminate the primary tumor and generate tumor-associated antigens, which could elicit antitumor immune responses. Herein, we report on the rational design and fabrication of copper sulfide (CuS)-based nanoplatform for cancer photothermal immunotherapy. The as-prepared core-shell CuS@mSiO2-PFP-PEG (CPPs) nanocomposites possess high biocompatibility, photoacoustic (PA)/ultrasound (US) imaging, and strong PTT effect upon 808 nm laser irradiation, indicating that the nanocomposites have a promising application in diagnosis and treatment of breast cancer with molecular classification. Importantly, we also elucidated that the CPP-triggered PTT in combination with anti-PD-1 checkpoint blockade therapy can not only obliterate primary tumor but also inhibit metastatic tumor in tumor-bearing mice. We believe that the CPPs have a good probability to serve as a useful nanoplatform for PTT, and this approach may provide a promising strategy for tumor-therapeutic modality with immunotherapy.

Entities:  

Keywords:  CuS; immunotherapy; mesoporous silica nanoparticle; photothermal therapy; theranostic nanomedicine; tumor metastasis

Mesh:

Substances:

Year:  2020        PMID: 33073973     DOI: 10.1021/acsami.0c16526

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  8 in total

Review 1.  Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.

Authors:  Su-Ran Li; Fang-Yi Huo; Han-Qi Wang; Jing Wang; Chun Xu; Bing Liu; Lin-Lin Bu
Journal:  J Nanobiotechnology       Date:  2022-06-14       Impact factor: 9.429

Review 2.  Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy.

Authors:  Jin Zhang; Yandai Lin; Zhe Lin; Qi Wei; Jiaqi Qian; Renjie Ruan; Xiancai Jiang; Linxi Hou; Jibin Song; Jianxun Ding; Huanghao Yang
Journal:  Adv Sci (Weinh)       Date:  2021-12-19       Impact factor: 16.806

Review 3.  Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer.

Authors:  Yujie Zhao; Xu Liu; Xinyu Liu; Jing Yu; Xin Bai; Xi Wu; Xinyu Guo; Zhihui Liu; Xiaowei Liu
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

Review 4.  Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy.

Authors:  Blanca Escriche-Navarro; Andrea Escudero; Elena Lucena-Sánchez; Félix Sancenón; Alba García-Fernández; Ramón Martínez-Máñez
Journal:  Adv Sci (Weinh)       Date:  2022-07-22       Impact factor: 17.521

Review 5.  Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment.

Authors:  Xin Yu; Chao Fang; Kun Zhang; Chunxia Su
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

Review 6.  Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes.

Authors:  Yang Xuan; Meng Guan; Shubiao Zhang
Journal:  Theranostics       Date:  2021-05-25       Impact factor: 11.556

7.  Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.

Authors:  Weixi Jiang; Lei Su; Meng Ao; Xun Guo; Chen Cheng; Yuanli Luo; Zhuoyan Xie; Xingyue Wang; Junrui Wang; Shuling Liu; Yang Cao; Pan Li; Zhigang Wang; Haitao Ran; Zhiyi Zhou; Jianli Ren
Journal:  J Nanobiotechnology       Date:  2021-07-05       Impact factor: 10.435

8.  Synergic fabrication of pembrolizumab loaded doxorubicin incorporating microbubbles delivery for ultrasound contrast agents mediated anti-proliferation and apoptosis.

Authors:  Huilin Liu; Xing Li; Zihe Chen; Lianjie Bai; Ying Wang; Weiyang Lv
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.